[
  {
    "ts": null,
    "headline": "Fidelity Magellan Fund Q3 2024 Review",
    "summary": "For Q3 2024, Fidelity Magellan Fund gained 3.28%, trailing the 5.89% advance of the benchmark S&P 500Â® index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=350ffa38759660022d913ce8b21d20c1a6008ab0c67ecd67c926145fe0429ad2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731624600,
      "headline": "Fidelity Magellan Fund Q3 2024 Review",
      "id": 131361864,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219272320/image_1219272320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, Fidelity Magellan Fund gained 3.28%, trailing the 5.89% advance of the benchmark S&P 500Â® index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=350ffa38759660022d913ce8b21d20c1a6008ab0c67ecd67c926145fe0429ad2"
    }
  },
  {
    "ts": null,
    "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
    "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
    "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731610380,
      "headline": "5 Healthcare Stocks to Buy in a Beaten-Up Sector",
      "id": 131357763,
      "image": "https://s.yimg.com/ny/api/res/1.2/QrvejPduXGfjO6QTtPWJsQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/a741676153df2123cda83c0fb107464e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "It has been a shaky time for healthcare stocks, but that only presents a buying opportunity.  The  Health Care Select Sector SPDR Fund  which owns shares of major U.S. health insurers, medical device makers, and drugmakers, has dropped about 7% since hitting a record high in mid-September.  Investors have been selling healthcare stocks, buying up more economically-sensitive ones instead, as the Federal Reserve has cut interest rates and the market accounts for the positive economic consequences from Republicans winning the White House and both chambers of Congress.",
      "url": "https://finnhub.io/api/news?id=4d43b62abf62a0a77f6d4a384ab6fde494be8b5a52146c38beceb7e7075fb787"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3be01bdd596c0746433835593b89978cf866f263c6d4fd46170f826f26e55369",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731601980,
      "headline": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "id": 131413510,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3be01bdd596c0746433835593b89978cf866f263c6d4fd46170f826f26e55369"
    }
  },
  {
    "ts": null,
    "headline": "Is AstraZeneca a Buy as It Eyes the Weight Loss Market?",
    "summary": "AstraZeneca just released some encouraging data about its weight loss drug candidates.",
    "url": "https://finnhub.io/api/news?id=1a9db489b890574ecef4853981c8a9cee6843f05fcbd2c060a38b8e4ec9ccedd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731586500,
      "headline": "Is AstraZeneca a Buy as It Eyes the Weight Loss Market?",
      "id": 131346800,
      "image": "https://g.foolcdn.com/editorial/images/797407/gettyimages-1186545957.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca just released some encouraging data about its weight loss drug candidates.",
      "url": "https://finnhub.io/api/news?id=1a9db489b890574ecef4853981c8a9cee6843f05fcbd2c060a38b8e4ec9ccedd"
    }
  },
  {
    "ts": null,
    "headline": "Surging diabetes rate underscores vast opportunity in weight-loss drugs",
    "summary": "Surging diabetes rate underscores vast opportunity in weight-loss drugs",
    "url": "https://finnhub.io/api/news?id=c0d74423f50ac96ed8eac63c6e2d5fdebe40b54b8da8bc8f1fcc84396d4b57da",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731586140,
      "headline": "Surging diabetes rate underscores vast opportunity in weight-loss drugs",
      "id": 131413513,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Surging diabetes rate underscores vast opportunity in weight-loss drugs",
      "url": "https://finnhub.io/api/news?id=c0d74423f50ac96ed8eac63c6e2d5fdebe40b54b8da8bc8f1fcc84396d4b57da"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Growth Stocks to Buy on the Dip",
    "summary": "Their recent issues are nothing to fret over for investors focused on the long game.",
    "url": "https://finnhub.io/api/news?id=024eef6bb024111c446d07f586c3fd8e9757755a60762391f680417cf5c2f6b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731585600,
      "headline": "2 Top Growth Stocks to Buy on the Dip",
      "id": 131346801,
      "image": "https://g.foolcdn.com/editorial/images/796832/person-working-at-a-desk.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Their recent issues are nothing to fret over for investors focused on the long game.",
      "url": "https://finnhub.io/api/news?id=024eef6bb024111c446d07f586c3fd8e9757755a60762391f680417cf5c2f6b7"
    }
  },
  {
    "ts": null,
    "headline": "3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years",
    "summary": "These are income stocks you can buy and hold forever.",
    "url": "https://finnhub.io/api/news?id=c03b99715eb7f6a975dd208b68c066f3651df1bd7a61cf7e48a295a39a0b1f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731583140,
      "headline": "3 Ultra-Safe Dividend Stocks That Have Been Paying Dividends for More Than 100 Years",
      "id": 131346802,
      "image": "https://g.foolcdn.com/editorial/images/797238/a-couple-looking-at-a-statement.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These are income stocks you can buy and hold forever.",
      "url": "https://finnhub.io/api/news?id=c03b99715eb7f6a975dd208b68c066f3651df1bd7a61cf7e48a295a39a0b1f07"
    }
  },
  {
    "ts": null,
    "headline": "BlackRock Large Cap Focus Growth Fund Q3 2024 Commentary",
    "summary": "BlackRock Large Cap Focus Growth Fund posted returns of 1.57% (Institutional shares) and 1.54% (Investor A shares, without sales charge) for the third quarter of 2024.",
    "url": "https://finnhub.io/api/news?id=ee48594e2db3ccc47564ec572c285ea40d32efc110cf8f831abacb5863e94c75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731581460,
      "headline": "BlackRock Large Cap Focus Growth Fund Q3 2024 Commentary",
      "id": 131350634,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1877547664/image_1877547664.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "BlackRock Large Cap Focus Growth Fund posted returns of 1.57% (Institutional shares) and 1.54% (Investor A shares, without sales charge) for the third quarter of 2024.",
      "url": "https://finnhub.io/api/news?id=ee48594e2db3ccc47564ec572c285ea40d32efc110cf8f831abacb5863e94c75"
    }
  },
  {
    "ts": null,
    "headline": "Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes",
    "summary": "The randomised, multi-centre, placebo-controlled, double-blind trial included 1,032 pre-diabetic individuals.",
    "url": "https://finnhub.io/api/news?id=c465d693286213099e8247ffee7945d0d6fcb3c76c1a6e4b6d13a211b995d10a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731580199,
      "headline": "Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes",
      "id": 131346803,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/11/CTA-1-Lilly-Obese-Shutterstock_1406931482.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The randomised, multi-centre, placebo-controlled, double-blind trial included 1,032 pre-diabetic individuals.",
      "url": "https://finnhub.io/api/news?id=c465d693286213099e8247ffee7945d0d6fcb3c76c1a6e4b6d13a211b995d10a"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Blue Chip Growth Fund Q3 2024 Quarterly Review",
    "summary": "For the quarter, FidelityÂ® Blue Chip Growth Fund's Retail Class shares gained 0.83%, lagging the 3.19% advance of the benchmark, the Russell 1000Â® Growth Index.",
    "url": "https://finnhub.io/api/news?id=f23c2413d003a839b02e25b060d177c3612427355108ffa08dd183a5efa64dda",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731576840,
      "headline": "Fidelity Blue Chip Growth Fund Q3 2024 Quarterly Review",
      "id": 131349041,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1158571591/image_1158571591.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For the quarter, FidelityÂ® Blue Chip Growth Fund's Retail Class shares gained 0.83%, lagging the 3.19% advance of the benchmark, the Russell 1000Â® Growth Index.",
      "url": "https://finnhub.io/api/news?id=f23c2413d003a839b02e25b060d177c3612427355108ffa08dd183a5efa64dda"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: conclusive phase III trial on tirzepatide",
    "summary": "Eli Lilly has presented the detailed results of a three-year Phase III trial evaluating tirzepatide . The laboratory reports that this weekly treatment significantly reduced the risk of progression to...",
    "url": "https://finnhub.io/api/news?id=fb27dab52b9ff32c53514c25ebe5d77032e5846f82f8f110c1c6f75f9df7e11c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731567377,
      "headline": "Eli Lilly: conclusive phase III trial on tirzepatide",
      "id": 131345737,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has presented the detailed results of a three-year Phase III trial evaluating tirzepatide . The laboratory reports that this weekly treatment significantly reduced the risk of progression to...",
      "url": "https://finnhub.io/api/news?id=fb27dab52b9ff32c53514c25ebe5d77032e5846f82f8f110c1c6f75f9df7e11c"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study",
    "summary": "Eli Lilly's Phase 3 SURMOUNT-1 study reports that tirzepatide reduced the progression of diabetes",
    "url": "https://finnhub.io/api/news?id=f23b84724be0d865c9cd9c04e6f63ad54e659c5de9f47b28bf565e0c01d73e26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731561868,
      "headline": "Eli Lilly's Tirzepatide Reduces Type 2 Diabetes Risk by 94% in Long-Term Study",
      "id": 131342236,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/e4f9c1d86005eb4211c084eb447eed40",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Phase 3 SURMOUNT-1 study reports that tirzepatide reduced the progression of diabetes",
      "url": "https://finnhub.io/api/news?id=f23b84724be0d865c9cd9c04e6f63ad54e659c5de9f47b28bf565e0c01d73e26"
    }
  }
]